<DOC>
	<DOC>NCT00887263</DOC>
	<brief_summary>The purpose of the study is to compare the efficacy and tolerability of budesonide 3 mg effervescent tablet (9 mg/day) compared to placebo for the treatment of patients with resistant oral cGvHD.</brief_summary>
	<brief_title>Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Karnofsky &gt;= 70 Oral chronic GvHD after allogeneic haematopoietic stem cell transplantation Oral cGvHD of erosive and/or ulcerative type NIH scale &gt;= 3 Resistant oral cGvHD with no oral response to conventional primary treatment Uncertain diagnosis of resistant oral cGvHD Symptomatic oral cGvHD of hyperkeratotic type solely Current active oral bacterial, viral, or fungal infection Unwilling to forego concurrent treatment for mucosal lesions and/or related oral pain Requiring addition of new systemic therapy including steroids, or radiation therapy Local intestinal infection Abnormal hepatic function or liver cirrhosis If careful medical monitoring is not ensured: tuberculosis, cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, infection Second line treatment of oral cGvHD with topical steroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>